Acupuncture for Chronic Radiation-Induced Xerostomia in Head and Neck Cancer: A Multicenter Randomized Clinical Trial

This study represents a major milestone in integrative oncology, being the first phase 3, multicenter, randomized controlled trial to investigate the efficacy of acupuncture for chronic radiation-induced xerostomia in patients with head and neck cancer. Conducted between 2013 and 2021 at 33 research centers across 13 US states, the study enrolled 258 patients who developed grade 2 or 3 xerostomia at least 12 months after completing radiotherapy. Xerostomia is a devastating complication that affects more than 50% of patients undergoing radiotherapy for head and neck cancer, causing difficulties with speaking, chewing, swallowing, and sleeping, along with significant dental and nutritional problems. Until now, no effective established treatments existed for this chronic condition.

The trial design was rigorously planned with three arms: true acupuncture (TA), sham acupuncture (SA), and standard oral hygiene (SOH). Participants in the acupuncture arms received treatment twice weekly for 4 weeks, with the option of an additional 4 weeks for minor responders. True acupuncture used 14 specific points based on traditional Chinese medicine and prior evidence, including auricular points (Shenmen, point 0, salivary gland 2-prime) and body points (CV-24, LU-7, LI-1-prime, KI-6). The sham arm used non-penetrating telescopic needles at inactive points, preserving participant blinding.

The primary endpoint was measured with the Xerostomia Questionnaire (XQ) at week 4, while quality of life was assessed with the FACT-G. The results demonstrated significant efficacy of true acupuncture. At week 4, the TA arm showed significantly lower xerostomia scores compared with SOH (50.6 vs. 57.3 points; difference of -6.67; p = 0.003).

Although the difference between TA and SA did not reach significance after adjustment for multiple comparisons (p = 0.04), a clear trend toward superiority was observed. More impressive was the partial response rate: 31.3% in the TA arm compared with just 17.1% in SA and 14.1% in SOH. The benefits of true acupuncture were maintained through week 12, with consistent improvements in quality of life as measured by the FACT-G. At week 4, the TA arm showed superior scores compared with SOH (101.6 vs.

97.7; difference of +3.91; p = 0.002). At week 12, the benefits intensified, with the TA arm surpassing both SA and SOH in quality of life. Treatment was notably safe, with only 6 adverse events reported in the entire trial (3 in each acupuncture arm), all mild to moderate, including facial edema, flu-like symptoms, joint pain, hypertension, headache, and local hematoma. It is important to note that the sham arm also showed some improvement over time, especially at week 26, suggesting possible non-specific effects of needle stimulation.

Treatment adherence was high, with 94.4% of participants receiving at least 6 of the 8 scheduled sessions. The clinical implications are substantial. Acupuncture offers a minimally invasive, low-cost, and safe therapeutic option for a condition that historically lacked effective treatments. The results are particularly encouraging given that participants had had chronic xerostomia for an average of 4.2 years after diagnosis.

Limitations include the inherent difficulty of creating a true placebo control in acupuncture, as even "inactive" points may have some physiologic effect. The study population was predominantly male (77.9%) and white (88.8%), limiting generalizability to other populations. In addition, most patients received only 4 weeks of treatment, with no maintenance sessions offered, which may explain the diminishing effects over time. Proposed mechanisms of action include increased local blood flow, release of vasodilatory neuropeptides such as VIP and CGRP, and central nervous system modulation.

Prior functional neuroimaging studies have shown activation of brain regions related to sensory processing and saliva production during true acupuncture. This trial establishes acupuncture as an evidence-based therapeutic option for chronic radiation-induced xerostomia, with important implications for supportive care guidelines in oncology.